FINNENCE ▪ THE WIRE FILE
THE WIRE · № 60911
Company■ Unclear/unknown
New Phase 3 trial: Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer — AstraZeneca
KINDCompany
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN2026-10-01 12:00 UTC
LAST UPDATE2026-10-01 12:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
AstraZeneca's ADC maintenance trial in ovarian cancer expands its oncology pipeline but is early-stage.
AstraZeneca expands ADC oncology footprint
CATALYST TO WATCH
Enrollment and interim efficacy data
MAIN RISK
ADC safety or efficacy may fall short
FULL DISPATCH
Sponsor: AstraZeneca; Status: Recruiting; Conditions: Epithelial Ovarian Cancer; Interventions: Torvutatug samrotecan, Bevacizumab; Enrollment: 950 (estimated); First posted: 2026-10-01; NCT: NCT07851025
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
SUBJECTAstraZeneca · AZN
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
New Phase 3 trial: A Phase 3 Study of [177Lu]Ludotadipep for Metastatic Castration-Resistant Prostate Cancer — FutureChem2026-10-01 12:00 UTC
New Phase 3 trial: A Phase 3 Study of [177Lu]Ludotadipep for Metastatic Castration-Resistant Prostate Cancer — FutureChem2026-10-01 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age — GlaxoSmithKline2026-10-01 12:00 UTC
New Phase 3 trial: A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age — GlaxoSmithKline2026-10-01 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor — Eli Lilly and Company2026-10-01 12:00 UTC
Phase 3 results posted: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor — Eli Lilly and Company2026-10-01 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: Atacicept in Subjects With IgA Nephropathy — Vera Therapeutics, Inc.2026-10-01 12:00 UTC
Phase 3 results posted: Atacicept in Subjects With IgA Nephropathy — Vera Therapeutics, Inc.2026-10-01 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia — Biosplice Therapeutics, Inc.2026-10-01 12:00 UTC
Phase 3 results posted: A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia — Biosplice Therapeutics, Inc.2026-10-01 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III) — BioXcel Therapeutics Inc2026-10-01 12:00 UTC
Phase 3 results posted: Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III) — BioXcel Therapeutics Inc2026-10-01 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.